1. Home
  2. CBLL vs GERN Comparison

CBLL vs GERN Comparison

Compare CBLL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CeriBell Inc.

CBLL

CeriBell Inc.

HOLD

Current Price

$22.41

Market Cap

790.1M

Sector

N/A

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.36

Market Cap

753.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBLL
GERN
Founded
2014
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
790.1M
753.3M
IPO Year
2024
1996

Fundamental Metrics

Financial Performance
Metric
CBLL
GERN
Price
$22.41
$1.36
Analyst Decision
Strong Buy
Buy
Analyst Count
6
7
Target Price
$24.67
$3.00
AVG Volume (30 Days)
553.7K
6.8M
Earning Date
02-24-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$82,813,000.00
$183,403,000.00
Revenue This Year
$37.43
$147.42
Revenue Next Year
$27.73
$39.42
P/E Ratio
N/A
N/A
Revenue Growth
37.93
522.13
52 Week Low
$10.01
$1.04
52 Week High
$26.04
$3.59

Technical Indicators

Market Signals
Indicator
CBLL
GERN
Relative Strength Index (RSI) 69.81 56.51
Support Level $20.39 $1.30
Resistance Level $22.96 $1.37
Average True Range (ATR) 0.97 0.06
MACD -0.22 -0.01
Stochastic Oscillator 79.57 39.93

Price Performance

Historical Comparison
CBLL
GERN

About CBLL CeriBell Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: